A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

Inclusion Criteria:

- Histological or cytological diagnosis of adenocarcinoma of the exocrine pancreas that
is metastatic (Stage IV) and not amenable to resection with curative intent.

- If present, clinically significant or symptomatic amounts of ascites should be drained
prior to Day 1.

- Have had no prior systemic treatment for metastatic disease. Prior adjuvant or
neo-adjuvant chemotherapy or radiochemotherapy (other than nab-paclitaxel) is allowed
if completed ≥3 months prior to enrollment and no lingering toxicities are present.

- Prior radiation therapy for treatment of cancer is allowed to <25% of the bone marrow.

- Phase 2: archival tumor tissue or be willing to provide a pre-treatment biopsy.

- Measurable or nonmeasurable but evaluable disease as defined by the Response
Evaluation Criteria in Solid Tumors (RECIST 1.1).

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.

- Discontinued all previous treatments for cancer ≥4 weeks prior.

- Adequate organ function.

- Life expectancy of at least 3 months.

Exclusion Criteria:

- Serious concomitant systemic disorder.

- Have received first line treatment for metastatic pancreatic cancer.

- Received prior treatment with nab-paclitaxel.

- Have known central nervous system malignancy or metastasis.

- Current hematologic malignancies.

- Participated within the last 30 days in a clinical trial involving an investigational
product.

- Women with a positive pregnancy test or lactating.

- Have endocrine pancreatic tumors or ampullary cancer.

- Currently enrolled in another clinical trial.

- Have a known additional malignancy that is progressing or required active treatment
within the past 1 year.

- Known allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug
formulations.

- Are taking certain anti-coagulant medications such as warfarin and are unable to be
switched to other similar medicines.